Jeb Hornsby, MD
Family Medicine · Hartselle, ALNPI 1063608727
Payments from drug & device makers
Across 223 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$494
- Otsuka America Pharmaceutical, Inc.$340
- Boehringer Ingelheim$320
- Abbott$305
- Takeda Pharmaceuticals U.S.A., Inc.$304
- Lilly USA, LLC$298
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $494 |
| Otsuka America Pharmaceutical, Inc. | 15 | $340 |
| Boehringer Ingelheim | 19 | $320 |
| Abbott | 14 | $305 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $304 |
| Lilly USA, LLC | 16 | $298 |
| Amgen | 19 | $298 |
| AstraZeneca | 18 | $270 |
| Exact Sciences | 12 | $204 |
| GSK | 10 | $175 |
| Pfizer | 8 | $147 |
| AbbVie | 4 | $103 |
| Jazz Pharmaceuticals Inc. | 5 | $98 |
| Genentech USA, Inc. | 5 | $87 |
| Corium, LLC | 4 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $43 |
| Merz North America, Inc. | 1 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $34 |
| Merck | 2 | $33 |
| Tris Pharma Inc | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Corcept Therapeutics | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
How this compares
$3,968 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 194 | $213,190 |
| OzempicSemaglutide | 124 | $119,331 |
| FarxigaDapagliflozin Propanediol | 101 | $100,301 |
| MounjaroTirzepatide | 89 | $96,887 |
| EliquisApixaban | 98 | $95,805 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $60,255 |
| TrulicityDulaglutide | 40 | $51,782 |
| XifaxanRifaximin | 12 | $38,122 |
| Repatha SureclickEvolocumab | 40 | $27,236 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,781 |
| XareltoRivaroxaban | 22 | $20,528 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 695 | $17,254 |
| LinzessLinaclotide | 16 | $11,605 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,296 |
| Gabapentin | 355 | $4,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $320 | $220,486209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $298 | $148,669129 claims |
| Novo NordiskOzempic | $494 | $119,331124 claims |
| AstraZenecaFarxiga | $270 | $100,301101 claims |
| PfizerEliquis | $147 | $95,80598 claims |
| GSKTrelegy Ellipta | $175 | $60,25585 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $41 | $38,12212 claims |
| AbbVieLinzess | $103 | $11,60516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Hartselle
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.